- Trial phase
- Not stated
- Time to market
- Unknown, DISC-0998 was not identified as a real development program in any accessible database.
- Why 1/10
- No catalyst is scheduled because DISC-0998 was not found in any public or ingested database; the drug likely does not exist as a current development program, so this report is rated neutral with a minimal impact score.
DISC-0998 does not appear in any publicly-tracked database or filing, it is likely an erroneous or obsolete code. Investors should focus on Disc Medicine's confirmed lead asset bitopertin (DISC-1459), which posted positive Phase 3 APOLLO topline data in October 2026 and is the primary value driver with an FDA decision expected mid-2027.
Price Chart
Executive Summary
DISC-0998, identified in an unverified filing hint for Disc Medicine, Inc. (Nasdaq: IRON), cannot be found in any public clinical trial, FDA action, press release, SEC filing, or other tracked database. The company is a real, well-capitalized hematology biotech with a strong analyst consensus (18 Buy/Strong Buy, mean price target $123.25) and institutional backing from FMR, BlackRock, and RA Capital. However, its confirmed pipeline consists of bitopertin (DISC-1459, Phase 3 APOLLO positive data Oct 2026), selcodebart, DISC-3405, and DISC-0974, none matching 'DISC-0998'. The drug name likely reflects a data error, an obsolete internal code, or a preclinical candidate not yet publicly disclosed.
How It Works
Unknown. DISC-0998 is not mentioned in any accessible clinical-trial registry, FDA filing, press release, or SEC filing, its mechanism and intended indication are entirely unverifiable.
Trial Status
No clinical trial record, press release, or SEC filing mentioning DISC-0998 could be located. The drug name does not appear in any of SecBot's ingested databases (ClinicalTrials.gov, FDA actions, catalysts, press releases, or SEC filings).
The Two-Sided Case
Upcoming Catalysts
- No catalysts identifiable for DISC-0998. For the parent company Disc Medicine, the key catalyst is the FDA decision on bitopertin (DISC-1459) for EPP/XLP, expected mid-2027 following positive Phase 3 APOLLO data (Oct 19, 2026).
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Disc Medicine, Inc. 424B5 IRON ·Originating report